Company RxSight, commercial supplier of premium customizable intraocular lenses, which can be installed after cataract surgery, attracted 118 million dollars, releasing 7,4 million shares in 16 dollars - the minimum price of the stated range from 16 to 18 dollars. Taking into account the actual IPO price, the total diluted market value of the company will be 448 million dollars.
RxSight Launches RxSight Light Adjustable Lens System, including RxSight Light adjustable lens and RxSight light delivery device, that is, it offers the first and only commercially available intraocular lens technology, allowing physicians to customize and optimize the clarity of vision in patients, who have undergone cataract surgery.
RxSight планирует листинг на бирже Nasdaq under the ticker RXST. J.P.. Morgan, BofA Securities и SVB Leerink.